338 related articles for article (PubMed ID: 10607684)
1. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
4. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.
Sato Y; Kojima M; Takata K; Morito T; Asaoku H; Takeuchi T; Mizobuchi K; Fujihara M; Kuraoka K; Nakai T; Ichimura K; Tanaka T; Tamura M; Nishikawa Y; Yoshino T
Mod Pathol; 2009 Apr; 22(4):589-99. PubMed ID: 19270642
[TBL] [Abstract][Full Text] [Related]
5. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
Lajoie G; Kumar S; Min KW; Silva FG
Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
[TBL] [Abstract][Full Text] [Related]
7. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
8. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
9. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
Beck JT; Hsu SM; Wijdenes J; Bataille R; Klein B; Vesole D; Hayden K; Jagannath S; Barlogie B
N Engl J Med; 1994 Mar; 330(9):602-5. PubMed ID: 8302342
[No Abstract] [Full Text] [Related]
10. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
12. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
13. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
Ikeda S; Chisuwa H; Kawasaki S; Ozawa J; Hoshii Y; Yokota T; Aoi T
J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
[TBL] [Abstract][Full Text] [Related]
14. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
[TBL] [Abstract][Full Text] [Related]
15. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
Nishimoto N; Kishimoto T; Yoshizaki K
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
[TBL] [Abstract][Full Text] [Related]
16. [Transitional type of Castleman's disease manifested as the POEMS syndrome].
Tomić I; Plavec G; Tasić O; Ristanović A; Cvijanović V
Vojnosanit Pregl; 2004; 61(4):439-44. PubMed ID: 15552541
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.
Chabchoub I; Salah RB; Kallel R; Snoussi M; Frikha F; Marzouk S; Boudawara TS; Bahloul Z
Rom J Intern Med; 2024 Mar; 62(1):20-32. PubMed ID: 37948573
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman's Disease.
Hu C; Zou Y; Pan J; Yang J; Yang T; Tan T; Li J
Med Sci Monit; 2020 Aug; 26():e924783. PubMed ID: 32873770
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
Yoshizaki K; Matsuda T; Nishimoto N; Kuritani T; Taeho L; Aozasa K; Nakahata T; Kawai H; Tagoh H; Komori T
Blood; 1989 Sep; 74(4):1360-7. PubMed ID: 2788466
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement].
Akahane D; Kimura Y; Sumi M; Sashida G; Gotoh A; Miyazawa K; Ohyashiki K
Rinsho Ketsueki; 2006 Aug; 47(8):748-52. PubMed ID: 16986713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
